Delivery Order 75N91019D00012-75N91019F00129
Award Date
1/23/19
Potential Completion Date
2/24/19
Potential Value
$2.4K
Federal Agency
National Cancer Institute
Awardee
IIT Research Institute
Ultimate Awardee
Illinois Institute Of Technology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Chicago, IL 60616, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
7
Legislative Mandate
Walsh Healy Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $2,398.74 delivery order against the PREVENT Preclinical Drug Development Program indefinite-delivery/indefinite-quantity master contract to IIT Research Institute. IIT Research Institute, a subsidiary of the Illinois Institute Of Technology Sponsored Research And Programs Division, will provide a "CONTRACT ORIENTATION AND KICKOFF MEETING" as the prime contractor. The...
This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...
This federal contract award was issued by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology (IIT). The $1,405,361.18 delivery order contract supports the PREVENT Preclinical Drug Development Program, a significant $150 million multiple-award IDIQ contract with NCI. Under this task order, IITRI will provide topical resatorvid for nonmelanoma skin cancer prevention research during the period of September 2020 to...
This federal contract award from the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, is for a $596,209 Firm Fixed Price Delivery Order under the "PREVENT Cancer Program (PREVENT)" contract vehicle. The contract is for the "NOVEL ANDROGEN RECEPTOR ANTAGONIST-MEDIATED CHEMOPREVENTION OF PROSTATE CANCER" project, which aims to conduct preclinical research to support the development of therapies for...
This is a delivery order issued under the PREVENT Preclinical Drug Development Program contract, a $150 million multiple-award indefinite delivery/indefinite quantity (IDIQ) contract with the National Cancer Institute (NCI). The award to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology, is for the preclinical development of an RNA vaccine for immunoprevention of prostate cancer. The total value of this specific task order is $1,742,384.00. IITRI...
This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI) to IIT Research Institute (IITRI), a non-profit preclinical contract research organization (CRO). The contract is for $532,562.26 to evaluate a breast cancer prevention agent under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 million NCI Indefinite Delivery Vehicle (IDV) that IITRI holds. IITRI has extensive experience providing preclinical drug development services to federal agencies...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $597,893 firm fixed price delivery order to IIT Research Institute of Chicago, Illinois. This order was issued against the PREVENT Preclinical Drug Development Program multiple award contract vehicle to support a COVID-19 related study involving dogs. IIT Research Institute, a division of the Illinois Institute of Technology, will conduct the preclinical work in Chicago through March...
This federal contract award was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit organization and subsidiary of Temple University. The $1,570,991.00 task order is part of the PREVENT Preclinical Drug Development Program, which focuses on preclinical efficacy and intermediate endpoint biomarker testing for cancer prevention drug candidates. The task order is for a project titled...
This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit research organization and subsidiary of Temple University. The $988,252 firm fixed price contract is for research and development services in the area of biomedical basic research, specifically preclinical efficacy and biomarker analysis to support the NCI's PREVENT Cancer Preclinical Drug Development Program....
This federal contract award was issued by the National Cancer Institute, a civilian agency under the U.S. Department of Health and Human Services, to the University of Illinois for a "CONTRACT ORIENTATION AND KICKOFF MEETING" from September 30, 2015 to December 31, 2015. The award, which has a ceiling value of $2,587.19, is a delivery order under the PREVENT Toxicology and Pharmacology Testing (PREVENT TOX) indefinite delivery/indefinite quantity (IDIQ) contract. The contract has a...